Acta Med. 2007, 50: 109-111
https://doi.org/10.14712/18059694.2017.65
A Pilot Study of Matrix Metalloproteinases on the Model of Daunorubicin-induced Cardiomyopathy in Rabbits
References
1. P, Mabley JG, Liaudet L, Virág L, Szabó C, Pacher P. Matrix metalloproteinase activation is an early ebeny in doxorubicin-induced cardiotoxicity. Oncol Rep. 2004; 11:505–8.
2. EH, Zhang J, Hasinoff BB, Clark JR Jr, Ferrans VJ. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol. 1997; 29(9):2415–30.
<https://doi.org/10.1006/jmcc.1997.0477>
3. R, Geršl V, Klimtová I, Šimůnek T, Macháčková J, Adamcová M. Anthracycline- induced cardiotoxicity. Acta Medica (Hradec Kralove). 2000; 43(3):75–82.
4. JS, Brower GL, Gardner JD et al. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 2004; 9:33–42.
<https://doi.org/10.1023/B:HREV.0000011392.03037.7e>
5. P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther. 2002; 300(3):862–7.
<https://doi.org/10.1124/jpet.300.3.862>
6. GK and Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29:225–29.
<https://doi.org/10.1016/0009-9120(96)00003-6>
7. T, Klimtová I, Kaplanová J, Mazurová Y, Adamcová M, Štěrba M, Hrdina R, Geršl V. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Failure 2004; 6:377–387.
<https://doi.org/10.1016/j.ejheart.2003.05.003>
